1-4 of 4
R. Pasquini
Close
Sort by
Journal Articles

Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study.

Neil Shah, R. Pasquini, P. Rousselot, S. Jootar, J. Holowiecki, A. Countouriotis, D. Dejardin, T. Hughes, Brian J. Druker
Journal: Blood
Blood (2006) 108 (11): 167.
https://doi.org/10.1182/blood.V108.11.167.167
Published: 2006
Journal Articles

Dasatinib (SPRYCEL®) 140 mg Once Daily (QD) vs 70 mg Twice Daily (BID) in Patients (pts) with Advanced Phase Chonic Myeloid Leukemia (ABP-CML) or Ph(+) ALL Who Are Resistant or Intolerant to Imatinib (im): Results of the CA180-035 Study.

Hagop Kantarjian, O. Ottmann, R. Pasquini, Y.T. Goh, D.W. Kim, J. VanTornout, A. Damokosh, N. Shah
Journal: Blood
Blood (2006) 108 (11): 746.
https://doi.org/10.1182/blood.V108.11.746.746
Published: 2006
Journal Articles

Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation

Ph. Guardiola, R. Pasquini, I. Dokal, J. J. Ortega, M. van Weel-Sipman, J. C. W. Marsh, S. E. Ball, F. Locatelli, C. Vermylen, R. Skinner, P. Ljungman, R. Miniero, P. J. Shaw, G. Souillet, M. Michallet, A. N. Bekassy, G. Krivan, P. Di Bartolomeo, C. Heilmann, L. Zanesco, J. Y. Cahn, W. Arcese, A. Bacigalupo, E. Gluckman
Journal: Blood
Blood (2000) 95 (2): 422–429.
https://doi.org/10.1182/blood.V95.2.422
Published: 2000
Journal Articles

Effects of Plasmin on Human Factor VIII (AHF)

R. Pasquini, M.D., E. J. Hershgold, M.D.
Journal: Blood
Blood (1973) 41 (1): 105–111.
https://doi.org/10.1182/blood.V41.1.105.105
Published: 1973